Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-Label, First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

NCT05145179 is registered in ClinicalTrials.gov with Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT05145179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05145179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-Label, First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 1, 2021
Completion date
June 1, 2024
Enrollment
162 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

receptor, erbb-2